Amply™ Technology is the only available technology to increase the stability of heterohybridoma!
Due to their flexibility and easy access, hybridoma cell lines are key cell lines for diagnostic development. Unfortunately, many problems come tarnish this great tool and affect both the viability and profitability of your project in a very competitive market.
Most of the time, monoclonal antibodies are derived from unstable heterohybridomas, coming from the fusion of a SP2 mouse myeloma with another specie. You are consequently compelled to fuse again and again this heterohybridoma to a new B cell in order to maintain the cohesion of your clone.
Partners often come to Amplycell with poor-yield producers, or producers which have showed degenerecence or reduction of monoclonality over the time.